drugset / Trial / NCT00530452
Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and efficacy of 3 loading and maintenance dose levels of CG100649 administered for 21 days in the treatment of osteoarthritis pain.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Polmacoxib | Other / unclassified | 0.3 mg | Oral |
| Subject | Polmacoxib | Other / unclassified | 0.6 mg | Oral |
| Subject | Polmacoxib | Other / unclassified | 1.2 mg | Oral |